We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Halozyme Therapeutics, Inc.
Health Care · Biotechnology
Structural: ENHANZE is the de facto standard for SC-converting blockbuster biologics - 13+ partnered programs, royalty stack compounds as each partner launches new SC formulations and gets uptake. Royalty model = ~85% gross margins, minimal R&D burden vs.
owning a pipeline. Mid-2027 cliff: Darzalex SC composition-of-matter IP expires, which threatens the largest royalty stream ($JNJ Darzalex Faspro ~50% of royalty revenue).
(1) Royalty mix shifts as $ARGX Vyvgart Hytrulo, $BMY Opdivo SC, $ROG Ocrevus SC, $JNJ Rybrevant SC ramp - reduces Darzalex concentration. (2) ENHANZE platform IP extends beyond 2030 on newer co-formulations (different patent families than Darzalex 2027 cliff).
(3) Buybacks aggressive - board has repeatedly authorized large repurchase programs, float shrinking. (4) Pharma pipeline of IV-to-SC conversions still has multi-year runway (oncology, immunology, rare disease). (5) Auto-injector business (Antares) adds proprietary product revenue, less royalty-cliff-sensitive.
(1) Darzalex 2027 IP cliff is the dominant overhang - biosimilar SC versions could compress the largest royalty line. (2) Partner concentration: $JNJ + $BMY + $ROG = bulk of revenue, partner business decisions (pricing, switching IV-only) flow straight through.
(3) Alternative SC delivery tech (Merck's MK-1084 platform, $ALT competing hyaluronidase variants) could erode pricing power on new deals. (4) Litigation/patent challenges from biosimilar makers ongoing. (5) Royalty model means no upside from operational leverage - top-line is capped by partner sell-through.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for HALO - only listicles and opinion pieces, which we filter out by default. See everything anyway.